Office of the Director, National Institutes of Health; Office of Biotechnology Activity; Recombinant DNA Research; Notice of a Meeting of an NIH Blue Ribbon Panel, 13006 [E8-4849]
Download as PDF
<![CDATA[
13006
Federal Register / Vol. 73, No. 48 / Tuesday, March 11, 2008 / Notices
Send comments to Susan G. Queen,
Ph.D., HRSA Reports Clearance Officer,
Room 10–33 Parklawn Building, 5600
Fishers Lane, Rockville, Maryland
20857. Written comments should be
received within 60 days of this notice.
Dated: March 4, 2008.
Alexandra Huttinger,
Director, Division of Policy Review and
Coordination.
[FR Doc. E8–4787 Filed 3–10–08; 8:45 am]
BILLING CODE 4165–15–P
Dated: March 4, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities.
[FR Doc. E8–4849 Filed 3–10–08; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
yshivers on PROD1PC62 with NOTICES
Office of the Director, National
Institutes of Health; Office of
Biotechnology Activity; Recombinant
DNA Research; Notice of a Meeting of
an NIH Blue Ribbon Panel
There will be a meeting of the NIH
Blue Ribbon Panel to advise on the Risk
Assessment of the National Emerging
Infectious Disease Laboratory at Boston
University Medical Center. The meeting
will be held on Thursday, March 13,
2008, at the National Institutes of
Health, Building 1, Wilson Hall, 1
Center Drive, Bethesda, Maryland
20892, from 8:30 a.m. to approximately
2 p.m.
Discussion will include the charge to
the Panel, an overview of the principles
of environmental protection laws, and
risk assessment studies.
For further information concerning
this meeting contact Ms. Laurie
Lewallen, Advisory Committee
Coordinator, Office of Biotechnology
Activities, Office of the Director,
National Institutes of Health, 6705
Rockledge Drive, Room 750, Bethesda,
MD 20892–7985, 301–496–9838,
lewallla@od.nih.gov.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed above in
advance of the meeting. Any interested
person may file written comments with
the panel by forwarding the statement to
the Contact Person listed on this notice.
The statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
VerDate Aug<31>2005
15:44 Mar 10, 2008
Jkt 214001
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
An agenda and any additional
information for the meeting will be
posted on the agency’s Web site:
https://www.nih.gov/about/director/acd/
index.htm.
Background information may be
obtained by contacting NIH OBA by email oba@od.nih.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Room 1068, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: John R. Glowa, PhD,
Scientific Review Officer, National Center for
Research Resources, or National Institutes of
Health, 6701 Democracy Blvd., 1 Democracy
Plaza, Room 1078, MSC 4874, Bethesda, MD
20892–4874, 301–435–0807,
glowaj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333, National Institutes of Health,
HHS)
Dated: March 3, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–4565 Filed 3–10–08; 8:45 am]
BILLING CODE 4140–01–M
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Name of Committee: National Center for
Research Resources Special Emphasis Panel
K01 SEP—Teleconference.
Date: March 31, 2008.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Room 1068, Bethesda, MD 20892.
(Telephone Conference Call)
Contact Person: John R. Glowa, PhD,
Scientific Review Officer, National Center
For Research Resources, or National
Institutes of Health, 6701 Democracy Blvd.,
1 Democracy Plaza, Room 1078, MSC 4874,
Bethesda, MD 20892–4874, 301–435–0807,
glowaj@mail.nih.gov.
Name of Committee: National Center for
Research Resources Special Emphasis Panel
Human Tissue and Organ Program (HTOP)
SEP.
Date: April 1, 2008.
Time: 2 p.m. to 4 p.m.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel Advanced Development of
Multivalent Filovirus (Ebola and Marburg)
Hemorrhagic Fever Vaccines.
Date: March 20, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Crowne Plaza Washington DC Silver
Spring, 8777 Georgia Avenue, Silver Spring,
MD 20910.
Contact Person: Lynn Rust, PhD, Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institutes of Health/NIAID, 6700B Rockledge
Drive, MSC 7616, Bethesda, MD 20892, (301)
402–3938, lr228v@nih.gov.
E:\FR\FM\11MRN1.SGM
11MRN1
]]>Agencies
[Federal Register Volume 73, Number 48 (Tuesday, March 11, 2008)]
[Notices]
[Page 13006]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-4849]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Office of
Biotechnology Activity; Recombinant DNA Research; Notice of a Meeting
of an NIH Blue Ribbon Panel
There will be a meeting of the NIH Blue Ribbon Panel to advise on
the Risk Assessment of the National Emerging Infectious Disease
Laboratory at Boston University Medical Center. The meeting will be
held on Thursday, March 13, 2008, at the National Institutes of Health,
Building 1, Wilson Hall, 1 Center Drive, Bethesda, Maryland 20892, from
8:30 a.m. to approximately 2 p.m.
Discussion will include the charge to the Panel, an overview of the
principles of environmental protection laws, and risk assessment
studies.
For further information concerning this meeting contact Ms. Laurie
Lewallen, Advisory Committee Coordinator, Office of Biotechnology
Activities, Office of the Director, National Institutes of Health, 6705
Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-9838,
lewallla@od.nih.gov.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed above in
advance of the meeting. Any interested person may file written comments
with the panel by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one form
of identification (for example, a government-issued photo ID, driver's
license, or passport) and to state the purpose of their visit.
An agenda and any additional information for the meeting will be
posted on the agency's Web site: https://www.nih.gov/about/director/acd/
index.htm.
Background information may be obtained by contacting NIH OBA by e-
mail oba@od.nih.gov.
Dated: March 4, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities.
[FR Doc. E8-4849 Filed 3-10-08; 8:45 am]
BILLING CODE 4140-01-P
